سعر استراسبتيف 21 قرص 0.25 مجم / 0.035 مجم 2024

Norgestimate 0.25 mg + ethinylestradiol 0.035 mg tablets, 21 tablets (Hi-Pharm).

• Prevention of pregnancy in females of reproductive potential.Population: Females of reproductive potentialDailyMed (U.S. National Library of Medicine)
• Directory indication: contraceptive.

• Most common in clinical trials (2% or more): headache/migraine, abdominal/gastrointestinal pain, vaginal infection, genital discharge, breast issues (pain, discharge, enlargement), mood disorders, flatulence, nervousness and rash.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• High risk of arterial or venous thrombotic disease (e.g., smokers over 35 years, current or past DVT/PE, hypercoagulopathies, cerebrovascular or coronary artery disease, thrombogenic valvular or rhythm disease, uncontrolled hypertension, diabetes with vascular disease, migraine with aura or any migraine over age 35); liver tumours or liver disease; undiagnosed abnormal uterine bleeding; pregnancy; current or past breast cancer or other estrogen- or progestin-sensitive cancer; use of hepatitis C combinations containing ombitasvir/paritaprevir/ritonavir with or without dasabuvir.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Boxed warning: cigarette smoking increases the risk of serious cardiovascular events from COC use, especially in women over 35 years; COCs are contraindicated in women over 35 who smoke.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Stop if a thrombotic event occurs and at least 4 weeks before through 2 weeks after major surgery; start no earlier than 4 weeks after delivery in non-breastfeeding women; discontinue if jaundice occurs; monitor blood pressure in hypertensive women; monitor prediabetic and diabetic women; evaluate new or worsening headaches and irregular bleeding or amenorrhea.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• CYP3A4 inducers (e.g., phenytoin, barbiturates, carbamazepine, bosentan, felbamate, griseofulvin, oxcarbazepine, rifampicin, topiramate, rifabutin, rufinamide, aprepitant, St. John's wort)May decrease COC concentrations and contraceptive effectiveness or increase breakthrough bleeding; use a back-up or alternative contraceptive method.DailyMed (U.S. National Library of Medicine)
• Ombitasvir/paritaprevir/ritonavir with or without dasabuvirContraindicated because of the potential for ALT elevations.DailyMed (U.S. National Library of Medicine)

• Contraindicated in pregnancy because there is no reason to use COCs during pregnancy; there is little or no increased risk of birth defects in women who inadvertently use COCs during early pregnancy. Do not use COCs to induce withdrawal bleeding as a pregnancy test.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Advise nursing mothers to use other forms of contraception, when possible, until the child is weaned; COCs can reduce milk production, and small amounts of the steroids and/or metabolites are present in breast milk.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

English text not available for this section.